豆改善非糖尿病胰岛素耐药志愿者肥胖的胰岛素平衡:一个交叉随机对照试验
Lea Sani1, Nicolas Cardinault2, Julien Astier1
1Centre for Nutrition and Cardiovascular Disease (C2VN), INSERM, INRAE, AIX Marseille University, 13000 Marseille, France.
Antioxidants (Basel, Switzerland)
|August 26, 2023
概括
补充标准化木提取物粉末 (PPEP) 改善了肥胖,胰岛素耐药个体的胰岛素稳定性. 这种天然蜜蜂产品可能有助于预防2型糖尿病 (T2DM) 的发展.
科学领域:
- 生物化学 生物化学
- 内分泌学 在内分泌学.
- 营养科学 营养科学
背景情况:
- 蜂是一种富含多的蜜蜂衍生树脂,具有治疗性质.
- 中的多可能在预防2型糖尿病 (T2DM) 等慢性疾病方面发挥作用.
- 肥胖症中的胰岛素抵抗是T2DM的前体,强调了需要进行干预的需要.
研究的目的:
- 评估标准化树提取物粉末 (PPEP) 补充剂对胰岛素平衡的影响.
- 研究PPEP对非糖尿病肥胖个体的胰岛素敏感性和耐药性的影响.
主要方法:
- 一个随机的,受控的,交叉试验,涉及9名非糖尿病,胰岛素抵抗和肥胖的志愿者.
- 参与者在交叉设计中接受了安慰剂或PPEP补充剂3个月.
- 胰岛素平衡的生物标志物和人形数据在基线和干预后收集.
主要成果:
- 补充PPEP显著改善了胰岛素敏感性.
- 观察到胰岛素耐药性受试者的百分比显著下降.
- 胰岛素敏感度松达指数 (ISI-M) 显示显著改善.
结论:
- 标准化的PPEP补充剂有效地提高了肥胖,胰岛素耐药个体的胰岛素平衡.
- PPEP显示在减轻胰岛素抵抗和改善胰岛素分泌方面有潜力.
- 树可以提供针对T2DM病理生理机制的预防策略.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
230
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
230
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.3K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.3K
Oral Hypoglycemic Agents: Glinides
184
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
184
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
205
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
205
Hormones Regulating Blood Glucose
3.5K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.5K
Dipeptidyl Peptidase 4 Inhibitors
211
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
211


